Enhanced sonophoretic delivery of 5-aminolevulinic acid: preliminary human ex vivo permeation data

Authors

  • Gayathri Krishnan,

    1. Curtin Health Innovation Research Institute, School of Pharmacy, Curtin University, Perth, WA, Australia
    Search for more papers by this author
  • Jeffrey E. Grice,

    1. Therapeutics Research Centre, School of Medicine, The University of Queensland, QLD, Australia
    Search for more papers by this author
  • Michael S. Roberts,

    1. Therapeutics Research Centre, School of Medicine, The University of Queensland, QLD, Australia
    2. School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia
    Search for more papers by this author
  • Heather A. E. Benson,

    1. Curtin Health Innovation Research Institute, School of Pharmacy, Curtin University, Perth, WA, Australia
    Search for more papers by this author
  • Tarl W. Prow

    Corresponding author
    1. Dermatology Research Centre, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia
    • Curtin Health Innovation Research Institute, School of Pharmacy, Curtin University, Perth, WA, Australia
    Search for more papers by this author

Address:

Tarl W. Prow

Princess Alexandra Hospital

University of Queensland

Level 2 Building 33

Brisbane, 4102, Queensland

Australia

Tel: +61 7 3240 5840

Fax: +61 7 3176 5806

e-mail: t.prow@uq.edu.au.

Abstract

Background/aims

5-Aminolevulinate (ALA) is an important photodynamic therapy drug for the treatment of actinic keratoses and other non-melanoma skin cancers in cosmetically sensitive areas. One limitation of this drug is a relatively high recurrence rate. Our aim was to evaluate the feasibility of ultrasound augmented ALA delivery in excised human skin.

Materials and methods

An ultrasonic delivery device was used to enhance radiolabelled ALA into excised skin. Quantification of ALA was performed after passive and ultrasonic ALA delivery. Transepidermal water loss was used as a measure of barrier function before and after ultrasonic treatment.

Results

We found that ultrasonic treatment dramatically increased the mean cumulative amount of ALA to P< 0.0001 from 4 to 8 h when compared to passive ALA treatment. The flux was calculated to be 54.8 ± 8.0 μg/cm2 h with ultrasound treatment. TEWL increased nearly two-fold, from 12.3 to 21.0, after ultrasound treatment.

Conclusion

Our study supports the use of ultrasound for improved ALA delivery by showing significant improvements in the cumulative drug load and flux via combined ultrasound and ALA treatment.

Ancillary